Puma Biotechnology (PBYI) Reaches New 1-Year High and Low at $50.15

Puma Biotechnology (NASDAQ:PBYI)’s share price reached a new 52-week high and low on Thursday . The stock traded as low as $50.15 and last traded at $51.15, with a volume of 13342 shares trading hands. The stock had previously closed at $51.45.

PBYI has been the subject of several research analyst reports. Zacks Investment Research upgraded Puma Biotechnology from a “sell” rating to a “hold” rating in a report on Friday, January 26th. Credit Suisse Group set a $106.00 price target on Puma Biotechnology and gave the company a “buy” rating in a report on Thursday, April 26th. Stifel Nicolaus set a $95.00 price target on Puma Biotechnology and gave the company a “buy” rating in a report on Friday, March 9th. Barclays cut their price target on Puma Biotechnology from $92.00 to $90.00 and set an “overweight” rating for the company in a report on Friday, March 2nd. Finally, BidaskClub cut Puma Biotechnology from a “buy” rating to a “hold” rating in a report on Friday, January 26th. One analyst has rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $99.20.

Get Puma Biotechnology alerts:

The company has a current ratio of 1.91, a quick ratio of 1.87 and a debt-to-equity ratio of 0.85.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.65) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.26) by $0.61. The company had revenue of $66.50 million during the quarter, compared to analysts’ expectations of $67.33 million. During the same quarter last year, the firm posted ($1.16) EPS. sell-side analysts anticipate that Puma Biotechnology will post -3.83 EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the company. Teacher Retirement System of Texas boosted its holdings in shares of Puma Biotechnology by 314.1% in the 4th quarter. Teacher Retirement System of Texas now owns 10,129 shares of the biopharmaceutical company’s stock worth $1,001,000 after purchasing an additional 7,683 shares during the period. AXA purchased a new position in Puma Biotechnology during the 4th quarter valued at $1,052,000. C WorldWide Group Holding A S boosted its holdings in Puma Biotechnology by 9.3% during the 1st quarter. C WorldWide Group Holding A S now owns 23,882 shares of the biopharmaceutical company’s stock valued at $1,625,000 after acquiring an additional 2,026 shares during the period. Geode Capital Management LLC boosted its holdings in Puma Biotechnology by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 290,691 shares of the biopharmaceutical company’s stock valued at $28,733,000 after acquiring an additional 7,772 shares during the period. Finally, Castleark Management LLC boosted its holdings in Puma Biotechnology by 90.6% during the 4th quarter. Castleark Management LLC now owns 68,985 shares of the biopharmaceutical company’s stock valued at $6,819,000 after acquiring an additional 32,800 shares during the period. Hedge funds and other institutional investors own 97.95% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)).

5 Ways You're Sabotaging Your Retirement

Countless workers look forward to retirement and the opportunity to do what they want with their time. But if you're not careful, retirement could end up being nothing more than an extended period of financial stress. Here are a few moves that could leave you distraught and cash-strapped during your golden years, so be sure to avoid them at all costs.

1. Investing too conservatively

An estimated 60% of Americans are investing too conservatively for the future. They're therefore limiting their savings' growth and increasing their risk of running out of money down the line. While it's natural to want to avoid losses, the fact of the matter is that if you give yourself ample time to ride out the stock market's ups and downs, you're more likely than not to come out ahead. By contrast, if you play it too safe, you'll increase your chances of not having enough money when you need it.

IMAGE SOURCE: GETTY IMAGES.

Imagine you're able to save $200 a month for retirement over a 30-year time frame. Invest that money at an average annual 7% return, which is more than doable with stocks, and you'll wind up with $227,000 to work with. Stick to safer investments, like bonds, on the other hand, and you'll be looking at more like 3%, which will leave you with just $114,000 instead.

If you're still 10 years or more away from retirement, it absolutely pays to load up on stocks in your portfolio. Even if you're much closer to that milestone, you should still put some of your savings into stocks to maximize growth while you can.

2. Relying too heavily on Social Security

Millions of seniors today collect Social Security, and those benefits help them pay their living expenses in the absence of an actual paycheck. But if you think you can live on those benefits alone, you're sorely mistaken. Social Security is designed to replace about 40% of the average worker's pre-retirement income. Most people, however, need closer to 80% of their former earnings to pay the bills when they're older. Therefore, if your plan is to neglect your savings, you'll likely to run out of money in the future. So don't do that. Make regular IRA or 401(k) contributions, and aim to ramp up your savings rate as much as you can over time.

3. Filing for Social Security too early

Though your Social Security benefits are calculated based on your personal earnings record, filing for them too early could cause your payments to shrink. That's why it pays to wait until full retirement age to take benefits -- in doing so, you guarantee that your payments aren't reduced. Most Americans, however, don't know their full retirement age (hint: It's either 66, 67, or somewhere in between), and even among those who do, many still opt to file for Social Security at the earliest possible age of 62. Doing so, however, could severely limit what turns out to be your primary income stream in retirement, so be careful about when you file.

If you're wondering what sort of hit you might take by claiming benefits ahead of full retirement age, imagine that yours is 67 and that you're entitled to a full monthly benefit of $1,600 at that time. Filing at 62 will cut that benefit down to $1,120, which means you'll reduce your annual income by over $5,700. Therefore, if you don't have a specific reason to take benefits right away, it's wise to hold off.

4. Not paying off debt

Americans are used to living with debt, whether it be of the mortgage, student loan, or credit card variety. The problem with carrying that debt into retirement, however, is that when you're living on a fixed income, you might struggle to afford those nagging payments. And the longer you hang on to that debt, the more money you'll throw away on interest.

It's estimated that nearly 50% of seniors 75 and older continue to carry debt, so don't put yourself in a position where you end up joining their ranks. Figure out which of your debts are costing you the most (it's probably your credit cards) and work on paying down your outstanding obligations before your career comes to a close. You may need to cut corners in your budget to allow for that, but you'll appreciate the effort when your limited retirement income isn't being eaten up by debt payments.

5. Not having a plan

There's a reason retirement increases the likelihood of suffering from depression by 40% -- when you go from a 40-hour workweek to having little to do with your time, it can wreak havoc on your well-being. One of the worst mistakes you could make going into retirement is not having a plan for how you'll spend your days. So be kinder to yourself by mapping one out. Maybe you'll take that French literature class you were always interested in at your local community college, or round up friends for weekly museum outings. The possibilities are pretty much endless, but go in with a solid idea of how you'll occupy yourself so you don't wind up feeling bored and restless.

You deserve a rewarding retirement, so don't ruin your chances of achieving that goal. Steer clear of the aforementioned mistakes, and with any luck, you'll come to enjoy your golden years to the fullest.

Deutsche Bank AG Boosts Position in Ampco-Pittsburgh Corp (AP)

Deutsche Bank AG boosted its holdings in Ampco-Pittsburgh Corp (NYSE:AP) by 117.3% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 19,599 shares of the industrial products company’s stock after purchasing an additional 10,578 shares during the quarter. Deutsche Bank AG’s holdings in Ampco-Pittsburgh were worth $242,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of AP. Renaissance Technologies LLC raised its stake in shares of Ampco-Pittsburgh by 2.5% during the fourth quarter. Renaissance Technologies LLC now owns 271,200 shares of the industrial products company’s stock valued at $3,363,000 after purchasing an additional 6,700 shares during the period. Adirondack Research & Management Inc. raised its stake in shares of Ampco-Pittsburgh by 41.5% during the fourth quarter. Adirondack Research & Management Inc. now owns 83,141 shares of the industrial products company’s stock valued at $1,031,000 after purchasing an additional 24,386 shares during the period. BlackRock Inc. raised its stake in shares of Ampco-Pittsburgh by 2.7% during the fourth quarter. BlackRock Inc. now owns 600,154 shares of the industrial products company’s stock valued at $7,442,000 after purchasing an additional 15,807 shares during the period. Wells Fargo & Company MN raised its stake in shares of Ampco-Pittsburgh by 137.8% during the fourth quarter. Wells Fargo & Company MN now owns 14,950 shares of the industrial products company’s stock valued at $185,000 after purchasing an additional 8,664 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of Ampco-Pittsburgh by 6.1% during the third quarter. Dimensional Fund Advisors LP now owns 633,265 shares of the industrial products company’s stock valued at $11,020,000 after purchasing an additional 36,417 shares during the period. Hedge funds and other institutional investors own 58.41% of the company’s stock.

Get Ampco-Pittsburgh alerts:

In other news, major shareholder Louis Berkman Investment Co sold 14,411 shares of Ampco-Pittsburgh stock in a transaction that occurred on Monday, March 12th. The shares were sold at an average price of $11.13, for a total transaction of $160,394.43. Following the sale, the insider now owns 1,338,917 shares in the company, valued at $14,902,146.21. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 66,595 shares of company stock worth $737,497 in the last quarter. Insiders own 29.60% of the company’s stock.

AP opened at $9.55 on Tuesday. Ampco-Pittsburgh Corp has a 52-week low of $8.49 and a 52-week high of $18.59. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.52 and a quick ratio of 0.82.

Ampco-Pittsburgh (NYSE:AP) last posted its quarterly earnings data on Wednesday, March 14th. The industrial products company reported ($0.13) earnings per share (EPS) for the quarter. The firm had revenue of $114.40 million for the quarter, compared to analysts’ expectations of $109.00 million. Ampco-Pittsburgh had a negative net margin of 1.44% and a negative return on equity of 3.02%. equities research analysts forecast that Ampco-Pittsburgh Corp will post 0.51 earnings per share for the current year.

AP has been the topic of a number of analyst reports. ValuEngine lowered shares of Ampco-Pittsburgh from a “hold” rating to a “sell” rating in a research note on Saturday, February 3rd. Zacks Investment Research upgraded shares of Ampco-Pittsburgh from a “strong sell” rating to a “hold” rating in a research note on Friday, May 11th.

About Ampco-Pittsburgh

Ampco-Pittsburgh Corporation, together with its subsidiaries, manufactures and sells custom designed engineering products to commercial and industrial users worldwide. The company operates in two segments, Forged and Cast Engineered Products; and Air and Liquid Processing. The Forged and Cast Engineered Products segment produces forged hardened steel rolls that are used in cold rolling by producers of steel, aluminum, and other metals; ingot and open-die forged products for use in the oil and gas, and the aluminum and plastic extrusion industries; and cast rolls for hot and cold strip mills, medium/heavy section mills, hot strip finishing, roughing mills, and plate mills in various iron and steel qualities.

Want to see what other hedge funds are holding AP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ampco-Pittsburgh Corp (NYSE:AP).

Deutsche Bank chairman under fire ahead of AGM

Deutsche Bank AG (DBK.XE) Chairman Paul Achleitner faces fresh criticism ahead of the German bank's annual general meeting on Thursday.

Investment advisor Hermes EOS said Tuesday that the bank needs more effective leadership and should start considering plans for a new chairman.

"We urge Deutsche Bank to carefully consider the future composition of the supervisory board's nomination committee and use its reconstitution as an opportunity to review and improve the selection and nomination processes for management board members and nonexecutives respectively," Hans-Christoph Hirt, head of Hermes EOS at Hermes Investment Management, said in a statement.

"The nomination committee should also start to consider plans for the succession of Paul Achleitner," he added.

The chairman is "ultimately responsible for the limited progress Deutsche Bank has made during his tenure in the implementation of a value-creating strategy. Paul Achleitner will need to demonstrate more effective leadership at the top of the supervisory board," Mr. Hirt said.

Deutsche Bank reported a sharp decline in net profit in the first quarter of the year and in 2017 it reported its third-consecutive full-year loss.

Last month, the bank replaced its Chief Executive John Cryan with the senior head of its retail bank Christian Sewing.

Mr. Hirt criticized the way the appointment of the new CEO was handled.

"Paul Achleitner has not only overseen significant CEO and management board turnover during his six-year tenure but also a number of attempts to define and implement a value-creating strategy for Deutsche Bank. This included strategic U-turns, not least regarding both the bank's retail and asset management businesses, and to date, a failure to move decisively on the troubled investment bank," Mr. Hirt said.

Deutsche Bank declined to comment.

Deutsche Bank announced last month a overhaul of its corporate and investment bank business, as well as cost-cutting measures. The announcement didn't give many details and the German bank "could use the AGM to fill in the gaps," Goldman Sachs said in a research note.

Bloom Price Reaches $0.58 on Exchanges (BLT)

Bloom (CURRENCY:BLT) traded 6.6% higher against the U.S. dollar during the 1 day period ending at 16:00 PM ET on May 20th. Bloom has a market cap of $27.92 million and $265,036.00 worth of Bloom was traded on exchanges in the last 24 hours. One Bloom token can currently be bought for $0.58 or 0.00006858 BTC on major exchanges including Bibox, IDEX, Radar Relay and TOPBTC. During the last week, Bloom has traded 20.6% lower against the U.S. dollar.

Here is how similar cryptocurrencies have performed during the last 24 hours:

Get Bloom alerts: Ripple (XRP) traded 3.4% higher against the dollar and now trades at $0.70 or 0.00008221 BTC. Stellar (XLM) traded 3.7% higher against the dollar and now trades at $0.33 or 0.00003907 BTC. IOTA (MIOTA) traded up 2.6% against the dollar and now trades at $1.83 or 0.00021482 BTC. TRON (TRX) traded up 11.1% against the dollar and now trades at $0.0770 or 0.00000903 BTC. NEO (NEO) traded 5% higher against the dollar and now trades at $62.91 or 0.00737665 BTC. Tether (USDT) traded down 0.3% against the dollar and now trades at $1.00 or 0.00011714 BTC. VeChain (VEN) traded up 3.9% against the dollar and now trades at $4.53 or 0.00053174 BTC. Binance Coin (BNB) traded 1.5% lower against the dollar and now trades at $14.03 or 0.00164526 BTC. Zilliqa (ZIL) traded 2.9% higher against the dollar and now trades at $0.15 or 0.00001771 BTC. Ontology (ONT) traded 9.4% higher against the dollar and now trades at $7.94 or 0.00093074 BTC.

About Bloom

Bloom launched on November 29th, 2017. Bloom’s total supply is 150,000,000 tokens and its circulating supply is 47,742,434 tokens. The official website for Bloom is hellobloom.io. Bloom’s official Twitter account is @BloomToken and its Facebook page is accessible here. The Reddit community for Bloom is /r/BloomToken and the currency’s Github account can be viewed here.

Buying and Selling Bloom

Bloom can be bought or sold on the following cryptocurrency exchanges: IDEX, Upbit, Bittrex, Radar Relay, TOPBTC and Bibox. It is usually not possible to buy alternative cryptocurrencies such as Bloom directly using US dollars. Investors seeking to trade Bloom should first buy Bitcoin or Ethereum using an exchange that deals in US dollars such as Changelly, GDAX or Gemini. Investors can then use their newly-acquired Bitcoin or Ethereum to buy Bloom using one of the exchanges listed above.

NXP jumps on report Qualcomm deal is 'looking more optimistic'

Dutch semiconductor company NXP is jumping on a report that its proposed deal with U.S. chip giant Qualcomm is "looking more optimistic."

Shares jumped roughly 4 percent on the update, attributed to an anonymous Beijing official and included in a WSJ report about broader U.S.-China trade talks.

The proposed merger has been waiting for months on regulatory approval out of China.

Qualcomm CEO Steve Mollenkopf told CNBC in April that broader trade tensions between the two tech-heavy countries were stalling the deal.

"I think it'd be a very unusual situation for the rest of the world to approve something and then China not do it," Mollenkopf said at the time. "It's a good situation for China to get this deal done, and you know I have confidence that that'll happen."